Nina S. Kjellson Sells 7,779 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the transaction, the director now owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Tyra Biosciences Stock Performance

TYRA traded down $0.28 during midday trading on Tuesday, reaching $15.91. 187,035 shares of the company were exchanged, compared to its average volume of 297,086. The stock has a market capitalization of $805.05 million, a P/E ratio of -9.88 and a beta of 1.04. Tyra Biosciences, Inc. has a one year low of $12.34 and a one year high of $29.60. The stock’s 50-day simple moving average is $15.38 and its 200 day simple moving average is $19.20.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in TYRA. Janus Henderson Group PLC acquired a new stake in Tyra Biosciences during the 3rd quarter worth $24,994,000. Perceptive Advisors LLC increased its holdings in shares of Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in shares of Tyra Biosciences during the second quarter worth about $4,232,000. Ensign Peak Advisors Inc bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at about $3,047,000. Finally, American Century Companies Inc. lifted its holdings in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after purchasing an additional 145,346 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TYRA. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $22.00 to $31.00 in a report on Friday, October 18th. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Monday, January 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.